| Name | Title | Contact Details |
|---|
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
OptimizeRx® (OPRX) provides unique physician and consumer platforms and strategies to help patients better afford and adhere to their treatment regimens, while offering pharmaceutical and healthcare companies more effective ways to deliver relevant information and services to healthcare providers and their patients right at the point of care.
Quicksilver Scientific is a CLIA-certified laboratory that specializes in superior liposomal delivery systems, mercury testing and blood metal testing.
Canadian Healthcare Association is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
St. Louis Integrated health network is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.